NewsBenzinga엔라이벡스, 2b상 알로세트라 무릎 골관절염 임상시험 우선순위 조정 위한 비용 절감 계획 발표···2027년 중반까지 주요 데이터 발표 예정 엔라이벡스, 2b상 알로세트라 무릎 골관절염 임상시험 우선순위 조정 위한 비용 절감 계획 발표···2027년 중반까지 주요 데이터 발표 예정 Benzinga 2026.10.19 12:20 (GMT+0) Open on Benzinga Other news Here's How Much $1000 Invested In Coeur Mining 5 Years Ago Would Be Worth Today Anthropic Gives 5% of Itself to the Public. Musk Answers by Giving Away SpaceX Shares Standex International Appoints Samantha L. Stoddard As CFO Effective December 1, 2026 U.S. Transportation Secretary Duffy Expected To Announce Certification Of Boeing 737 Max 10 On Tuesday In Washington State Vivos Therapeutics Closes Its Acquisition Of An 11% Fully Diluted Equity Interest In Sod Sciences And A 50% Undivided Co-Ownership Interest In SOD's Pseudohypoxia Early‑Warning Test, The "Primed Cell For Chronic Disease" Test; Vivos Issued To SOD 12,000... 12 Industrials Stocks Moving In Monday's After-Market Session
U.S. Transportation Secretary Duffy Expected To Announce Certification Of Boeing 737 Max 10 On Tuesday In Washington State
Vivos Therapeutics Closes Its Acquisition Of An 11% Fully Diluted Equity Interest In Sod Sciences And A 50% Undivided Co-Ownership Interest In SOD's Pseudohypoxia Early‑Warning Test, The "Primed Cell For Chronic Disease" Test; Vivos Issued To SOD 12,000...
